Rationale of Combined PDT and SDT Modalities for Treating Cancer Patients in Terminal Stage-The Proper Use of Photosensitizer: A Reply
Xiaohuai Wang, MD 1 , Yifan Luo, PhD 2 , Doug Mitchell, PhD 3 , and Ralph W. Moss, PhD 4 Huang et al 1 have brought up some interesting points with regard to our article about sonodynamic and photodynamic therapy (SPDT) in advanced breast carcinoma. 2 We believe SPDT is a powerful systemic tumor target therapy. Com bined with conventional therapies, it makes cancer treatment safer and more effective. In this reply, we add further infor mation to our article.
Safety
SPDT as practiced in our clinic is much safer than conven tional tumor therapies, especially chemotherapy: a. The main sensitizer used, Sonoflora 1 (SF1), was supplied by SonneMed LLC, (Marlborough, NH). They have published zebra fish assay data indicat ing no evidence of toxicity. 3 b. To further enhance SPDT therapeutic efficacy, we have developed 2 new sensitizers, SFa and UF. All 3 are chlorin e6 based, and all showed no detect able side effects during multiple animal tests. c. Prior to use in clinical practice, the 3 sensitizers had been tested by The Drug Quality Research Institute, Guangdong Province, China, to verify safety for human use. Tests conducted by the insti tute showed that mice tolerated the sensitizers very well even at dosages 250 times higher than the dose used in our clinic. An official certificate has been issued allowing us to produce and commer cially use our sensitizer as foodstuff. d. Our ultrasound device also had been tested by a government laboratory and found to be safe for human use. e. Colleagues at the Dove Clinic 4 using a similar treatment protocol have also not found any safety problems. f. So far we have used SPDT with various combina tions of SF1, SFa, and UF to treat 81 patients with terminal cancer. We have safely conducted SPDT treatment more than 1000 times. SPDT is almost always well tolerated. The main side effects are (reversible) mild pain in tumor areas, tiredness, and weakness. Compared with chemotherapy and radiation therapy, it has almost no toxicity. SPDT does not induce photosensitive dermatitis, which may occur in conventional photodynamic therapy (PDT). SPDT shows none of the hand and foot syndromes that can occur with molecular target therapeutic drugs.
Sonodynamic Therapy (SDT)
Huang et al 1 argue that "to date, the correlation between ultrasound parameters and biological effects has not been fully established in preclinical investigation (in vitro or in vivo)":
a. The first point to note is that SDT has been very successful in treating a number of human cancers (results with more patients are being prepared for publication). There is no other reasonable expla nation to account for this. This is not the case with PDT, because light does not penetrate the body to reach deeper tumors. b. We have done much basic and preclinical research on SDT, of which some has been published, 5 alth ough more remains to be published. c. Various Russian researchers developed a chlorophyll based sensitizer, chlorin e6. 6 Their animal tests showed that after intraperitoneal (i.p.) injection, the chlorin e6 selectively accumulated in tumors. The maximum ratio of sensitizer levels were tumorto muscle at about 32, and tumourtoskin at about 44. These are much higher ratios than for Photofrin II and other earlier sensitizers. They very successfully used chlorin e6 PDT to treat patients with superficial tumors. c. Our sensitizers are also derived from chlorophyll, and our unpublished studies show them to be very selectively taken up by cancer cells. In one study, tumor bearing mice were killed 2 days after i.p. injection of sensitizer. Tumor and normal organs were then exposed to a red laser to activate sensi tizer fluorescence. Tumor tissue showed very strong fluorescence, with minimal fluorescence in healthy organs. There was no fluorescence in control mice. Confocal laser scanning microscopy confirmed this, with sensitizer only accumulating inside cancer cells, with almost none in normal cells such as muscle cells. Plasma, nephridium sphere, and hepatic collective areas showed the presence of minimal amounts of sensitizer. d. Fluorescence testing of mice with S180 sarcoma showed fluorescence on almost all skin during the first day after i.p. injection. It then rapidly disap peared from healthy skin within 2 days. The strong tumor specific fluorescence was seen for at least 2 weeks. The most specific and strongest tumor flu orescence was seen 24 to 72 hours after injection. e. These tests showed that SDT with SF1 did inhibit growth of mouse S180 sarcoma when exposed to ultrasound at 0.3 to 1.2 W/cm 2 for 3 minutes. 5 The inhibitory effects were ultrasound energy dependent. Pathological examination showed tumor coagu lated necrosis and vacuole degeneration, and this occurred very rapidly during a 36hour period. Fur ther tests showed that ultrasound penetrated the bone to affect deepseated tumors. f. We have done many further SDT animal studies using water transmitted ultrasound. Water conducts ultrasound almost as well as gel, but it is much more practical. 2, 5 Ethical Issues This center is registered with the Public Health Bureau, Baiyun Regional Office, Guangzhou, China and has received certification. d. Patients receive full disclosure about the therapy and sign informed consent forms. We only treat ter minal cancer patients who have failed conventional therapy or for whom there are no effective conven tional treatments available. Without SPDT therapy, these patients are unlikely to survive beyond a few months.
